FDA hits leukemia study with partial clinical hold
The FDA has placed a partial clinical hold on Xencor’s Phase I study of XmAb14045 on safety concerns.
Read More
Tag: XmAb14045
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
